<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00145535</url>
  </required_header>
  <id_info>
    <org_study_id>SLX41</org_study_id>
    <nct_id>NCT00145535</nct_id>
  </id_info>
  <brief_title>SOLX Titanium Sapphire Laser for Trabeculoplasty</brief_title>
  <official_title>SOLX Titanium Sapphire Laser for Trabeculoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SOLX, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of the Titanium Sapphire laser for laser trabeculoplasty to reduce intraocular pressure
      in patients with poorly controlled intraocular pressure on maximally tolerated medical
      therapy or prior failed laser trabeculoplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, outpatient study assessing equivalence of the Titanium Sapphire laser
      (TiSaLT) to the Argon laser (ALT) in the ability to reduce IOP in patients having primary
      open angle glaucoma in eyes with poorly controlled IOP on maximally tolerated medications
      and/or prior failed glaucoma surgery. Approximately 120 patients are to be enrolled in the
      study, with approximately equal numbers of patients enrolled at each of the investigational
      sites. The investigational sites are to accrue patients with poorly controlled open-angle
      glaucoma on maximal tolerated medical therapy and/or patients with previously failed laser
      trabeculoplasty. One half of the eyes will be randomized to treatment with the Argon laser
      (ALT) as the concurrent control group and the other half will be treated with Titanium
      Sapphire (TiSaLT) laser.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event frequency</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Glaucoma</condition>
  <condition>Glaucoma, Open Angle</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titanium sapphire laser treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Argon laser treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SOLX Titanium Sapphire Laser (TiSaLT)</intervention_name>
    <description>Spot laser treatment, ~50 spots over 180°</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Argon Laser Trabeculoplasty (ALT)</intervention_name>
    <description>Spot laser treatment, ~50 spots over 180°</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Clinical Diagnosis of Open Angle Glaucoma

          -  Patient is aged 18 years or older, with 2 sighted eyes.

          -  Eye to be treated have average IOP greater or equal to 22 mmHg, measured at 2
             pretreatment visits.

          -  Eye to be treated either exhibits:

          -  poorly controlled open angle glaucoma and on maximal tolerated medical therapy

          -  OR poorly controlled open angle glaucoma and failed previous laser trabeculoplasty
             (180° available to treat if previous ALT; can treat over previous SLT)

        Exclusion Criteria:

        Patients are not eligible for enrollment if any of the following exclusion criteria are
        met:

          -  Eye to be treated has any of the following:

               1. evidence of glaucoma other than open-angle glaucoma;

               2. severe paracentral or generalized field defect;

               3. any ocular condition that precluded adequate visualization and treatment of the
                  trabecular meshwork.

               4. prior glaucoma surgery other than laser trabeculoplasty or peripheral iridotomy.

          -  Patient has mental impairment such that he/she could not understand the protocol or is
             not in a position to provide written informed consent.

          -  Patient is pregnant.

          -  Patient might require other ocular surgery within the 6-month follow-up period.

          -  Patient has a medical history that suggested the potential for complications from
             TiSaLT.

          -  Having concurrent treatment with systemic steroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan S Peterson, MS, RAC</last_name>
    <role>Study Director</role>
    <affiliation>The EMMES Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Bay Eye Associates</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Eye Care</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Associates of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texan Eye Care</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mann Eye Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley EyeCare</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5L 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut du Glaucome de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1V 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>January 28, 2010</last_update_submitted>
  <last_update_submitted_qc>January 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Doug Adams</name_title>
    <organization>SOLX, Inc.</organization>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Glaucoma, open angle</keyword>
  <keyword>Intraocular Pressure</keyword>
  <keyword>Trabeculoplasty</keyword>
  <keyword>laser</keyword>
  <keyword>laser, surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

